13 results about "Protein antigen" patented technology

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The present application relates to a kind of preparation method and application of HPV recombinant protein therapeutic vaccine, belong to biological medicine technical field, the preparation method of the HPV recombinant protein therapeutic vaccine described includes: a plurality of complex lipid nanoparticles prepared by lipid are simultaneously wrapped and delivered HPV16HPV E6E7 recombinant protein antigen and nucleic acid TLR agonist adjuvant molecule.This application is beneficial to the recombinant protein therapeutic vaccine prepared to induce strong T cell immune response to HPV16E6E7 antigen, kill the cervical cancer cell infected by HPV.In addition, unlike the lipid nanoparticle (LNP) of mRNA vaccine delivery, there is no cation or ionizable lipid in the formula, significantly higher than mRNA vaccine in safety, with greater advantage than mRNA therapeutic vaccine, and low toxicity and side effects, vaccine effect is stable.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

The application relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 2, and the amino acid sequence of the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 3. Meanwhile, the application provides a PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is shown as SEQ ID NO. 4. On the basis of successfully expressing a PRV strain TK protein, the PRV strain TK protein is purified and used as an antigen to immunize mice, and a hybridoma technology is used to prepare a specific monoclonal antibody for the PRV strain TK protein, so as to provide an important tool for TK protein structure and function research of a PRV epidemic strain, and subsequent establishment of a PRV specific diagnosis method and related research.

A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

The application belongs to the technical field of immune detection, and specifically discloses a SMCP polyclonal antibody, a preparation method and application thereof. The preparation method comprises the following steps: using a polypeptide containing an amino acid sequence as shown in SEQ ID NO:1 as an immunogen to immunize animals, collecting whole blood of the immunized animals, and separating to obtain a SMCP polyclonal antibody. The application has the beneficial effect that: the specific SMCP protein antigen epitope is used as the immunogen to immunize animals, which is beneficial to large-scale preparation of the antibody specifically recognizing the SMCP protein. The SMCP antibody prepared by the method has good specificity, can be used for WB, IF and Co-IP experiments, and provides an important research tool for studying the pathogenic mechanism of weak sperm caused by SMCP deletion.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The application belongs to the technical field of biological medicine, and particularly relates to an African swine fever virus p30 protein antigen epitope peptide, a monoclonal antibody and application. The African swine fever virus p30 protein antigen epitope peptide is located at 140-155 aa of the p30 protein, and the amino acid sequence is shown as SEQ ID NO:1. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO:3; and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO:4. The monoclonal antibody can specifically recognize the antigen epitope peptide. The specific recognition of the antigen epitope peptide provides a basis for establishing an efficient method for detecting the African swine fever virus, and also lays a foundation for studying the structure and function of the p30 protein.

This invention provides a method for preparing a bovine coronavirus monoclonal antibody and its corresponding antigenic epitope peptide. The monoclonal antibody is prepared by immunizing animals with the N protein of bovine coronavirus as an antigen, followed by screening hybridoma cells. The amino acid sequence of the antigenic epitope peptide is SEQ ID NO:3. The antigenic epitope peptide obtained by this invention exhibits good exposure, facilitating efficient antibody recognition and ensuring the reliability and efficiency of the detection reaction. An indirect ELISA detection method established using this epitope peptide as the coating antigen significantly reduces non-specific binding and background interference compared to using the full-length N protein, resulting in a substantial improvement in detection specificity. In clinical sample validation, the concordance rate reached 100%, and no cross-reactivity was observed. Furthermore, in terms of sensitivity, this method can detect positive sera at higher dilutions, with a detection limit significantly superior to that of the full-protein antigen.

The present application relates to the field of immunological examination, in particular to a kind of capture microbead and preparation method and its use, the present application provides a kind of preparation method of capture microbead, comprising: (1), aldehyde / sulfate latex microspheres stock solution is diluted using zwitterionic buffer, then first centrifugation is discarded supernatant, and then resuspended and washed with zwitterionic buffer, then second centrifugation is discarded supernatant, and then resuspended with zwitterionic buffer, obtain aldehyde / sulfate latex microspheres resuspension;(2), restore protein antigen is added to aldehyde / sulfate latex microspheres resuspension, incubation, then centrifugation is discarded supernatant, obtain the aldehyde / sulfate latex microspheres coated with restore protein antigen, then blocking, washing, preservation is carried out;The capture microbead obtained by the above preparation method has high specificity, accuracy and precision when detecting anti-retinal antibody.

This disclosure provides compositions (e.g., pharmaceutical compositions) and related technologies (e.g., their components and / or related methods) for the delivery of malaria protein antigens. In particular, this disclosure provides polyribonucleotides encoding malaria protein antigens.

A respiratory syncytial virus (RSV) F protein comprising at least one modification or mutation for increasing the pre-fusion conformational stability of the RSV F protein selected from the group consisting of: (1) introducing one or more disulfide bonds in the RSV F protein; (2) introducing one or more amino acid mutations in the RSV F protein for filling a hydrophobic cavity; (3) introducing one or more amino acid mutations in the RSV F protein for electrostatic remodeling; and (4) removing the p27 peptide segment in the RSV F protein. The RSV F protein has high stability as a recombinant protein antigen, is easy to store and transport, has improved expression, is easy to achieve yield improvement, and the modified RSV F protein has higher immunogenicity and can produce better immune protection.